Clinicopathological and prognostic values of fibronectin and integrin αvβ3 expression in primary osteosarcoma

Background Osteosarcoma is a malignant bone tumor with a high potential for lung metastasis, and the prognosis for patients with metastatic disease is very poor. The interaction between fibronectin (FN) and integrin αvβ3 in soft-tissue sarcoma promotes cell migration, invasion, and lung metastasis. This study aimed to investigate the prognostic significance of FN and αvβ3 in osteosarcoma. Methods Immunohistochemistry and western blotting were used to detect the expression of FN and αvβ3 in 60 osteosarcoma specimens and in 30 osteochondroma specimens. Furthermore, correlations of FN and αvβ3 with the clinicopathological features of osteosarcoma patients were analyzed using the χ 2 test and Fisher’s exact test. Disease-free survival and overall survival of osteosarcoma patients were assessed using the Kaplan-Meier method and Cox proportional hazards model. The predictive accuracy of the model was determined by the Harrell concordance index. Results FN ( P < 0.05) and αvβ3 ( P < 0.05) were overexpressed in osteosarcoma specimens compared with osteochondroma specimens. High FN expression was associated with a poor response to chemotherapy ( P = 0.001) and poor disease-free ( P < 0.001) and overall ( P < 0.001) survival. High expression of αvβ3 was linked to an advanced surgical stage ( P = 0.028), a poor response to chemotherapy ( P = 0.002), and both poor disease-free survival ( P < 0.001) and overall survival ( P < 0.001). FN and αvβ3 co-expression were associated with sex ( P = 0.011), an advanced surgical stage ( P = 0.013), and a poor response to chemotherapy ( P = 0.002). Moreover, high expression of both proteins can serve as an independent prognostic value for reduced survival time in osteosarcoma patients. Conclusions The results of this study suggest that FN and αvβ3 expression is associated with an unfavorable clinical outcome of osteosarcoma, and these molecules may constitute attractive therapeutic targets for osteosarcoma treatment. To improve the survival of osteosarcoma patients, further investigations are required to clarify their prognostic values in a larger population.